Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 1406Neoplasms 1131Prostatic Neoplasms 746Lung Neoplasms 622Colorectal Neoplasms 598Carcinoma, Non-Small-Cell Lung 571Carcinoma, Hepatocellular 416Pancreatic Neoplasms 401Leukemia, Myeloid, Acute 398Stomach Neoplasms 356Multiple Myeloma 327Brain Neoplasms 313Ovarian Neoplasms 309Head and Neck Neoplasms 292Neoplasm Metastasis 277Precursor Cell Lymphoblastic Leukemia-Lymphoma 261Rectal Neoplasms 255Uterine Cervical Neoplasms 248Recurrence 248Melanoma 243Esophageal Neoplasms 237Glioblastoma 232Squamous Cell Carcinoma of Head and Neck 230Lymphoma 214Sarcoma 209Urinary Bladder Neoplasms 194Colonic Neoplasms 192Glioma 191Triple Negative Breast Neoplasms 190Hematologic Neoplasms 183

Interventions

sodium glycididazole 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × OTHER × Chemoradiotherapy × Clear all
NCT06667622 2024-10-31

Sodium Glycididazole Reduces the Adverse Reactions of Concurrent Chemoradiotherapy

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting
40 enrolled

Chemoradiotherapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡